ArticleBMC pediatrics2026
Long non-coding RNA IL6-AS1 promotes severe community-acquired pneumonia in children through the miR-149-5p/MAPK6 axis.
Article in BMC pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSevere community-acquired pneumonia (SCAP) seriously endangers children's lives. This study aimed to explore the potential regulatory mechanisms of long non-coding RNA IL6-AS1 (lncRNA IL6-AS1) in SCAP.
methodsThis study included 160 children with SCAP and 160 healthy controls. Lipopolysaccharide (LPS) was used to induce human embryonic lung fibroblasts (MRC-5) to construct an SCAP cell model. Functional experiments were conducted by combining real-time quantitative PCR, the cell counting kit-8 (CCK-8) assay, flow cytometry, and enzyme-linked immunosorbent assay (ELISA). The targeted regulatory relationship between different genes was verified through RNA immunoprecipitation (RIP) experiment and dual luciferase assay.
resultsIn children with SCAP, IL6-AS1 expression showed significant upregulation. IL6-AS1 has a strong diagnostic value for SCAP, and its expression was significantly positively correlated with indicators of inflammatory response intensity (C-reactive protein (CRP), lactate dehydrogenase (LDH), procalcitonin levels (PCT)) in affected children. It may emerge as an independent risk factor influencing the prognosis of SCAP patients, with significantly reduced cumulative survival rates observed in children exhibiting high IL6-AS1 expression. In vitro experimental results showed that IL6-AS1 could be dose-dependently up-regulated by LPS. Inhibiting IL6-AS1 expression could effectively alleviate the decrease in cell activity and increase in apoptosis levels induced by LPS, thereby reducing cell damage and inflammation imbalance. Moreover, IL6-AS1 targeted microRNA-149-5p (miR-149-5p), while miR-149-5p targeted mitogen-activated protein kinase 6 (MAPK6). Further experiments confirmed that concurrent inhibition of miR-149-5p alongside suppression of IL6-AS1 reversed the protective effects mediated by the former. Conversely, simultaneous knockdown of MAPK6 mitigated the cellular damage and inflammatory response induced by miR-149-5p inhibition.
conclusionsIL6-AS1 aggravated SCAP inflammatory response and cell damage through the miR-149-5p/MAPK6 axis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.